First Quarter 2024 Earnings

revvity

April 29, 2024

Safe Harbor

This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, plans concerning business development opportunities, acquisitions or divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. A detailed description of these risk factors can be found under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this presentation also contains non-GAAP financial measures. A reconciliation of these measures to the most directly comparable GAAP measures is included in the embedded hyperlink and is available on the “Financial Information” section of our website at www.revvity.com.

Key Takeaways

Innovation	Transformation	Performance
Launched Signals Clinical and Signals ChemDraw to build on existing SaaS capabilities	Recent Life Science leadership change cements integration strategy Cash flow process optimization efforts driving improved performance	Upside driven by Software and Diagnostics offsetting challenging Pharma environment Strong expense management

A Scientific Solutions Company Helping To Solve The World's Greatest Health Challenges From Discovery To Development, and Diagnosis to Cure

1Q24 Revenue Highlights

Segments

Diagnostics · Life Sciences



Geographic

AMERICAS · APAC · EU



Product Mix

RECURRING · NON-RECURRING



1Q24 Financial Results

ADJUSTED REVENUE	ADJUSTED OP MARGIN	ADJUSTED EPS	FREE CASH FLOW
$650M	**25.5%**	**$0.98**	**$132M**
⬇ -4% y/y	⬇ -250bps y/y	⬇ -3% y/y	⬆ +144% y/y
Organic: -3% | M&A: 0% | FX: 0%	Adj. Gross Margin: 60.8% | -150bps y/y	Adj. Tax Rate: 22.2%	Includes $22M of net AES related inflows
		Adj. Net Interest & Other: $11M	

Life Sciences

Product



REVENUE	
-8%	Organic Growth
Reported: -8% | M&A: 0% | FX: 0%	

AJUSTED OP MARGINS
33.6%
-580bps y/y

- -LDD decline from Pharma/Biotech, -LSD decline from Academic/Gov't
- -Mid-teens instruments decline, -HSD decline in reagents due to licensing comps and lower lab activity to start the year
- Strong software growth, new offerings off to a good start
- Margins pressured yr/yr due to lower volumes, mix, variable expenses

Diagnostics

End Market



REVENUE		AJUSTED OP MARGINS
1%	Organic Growth	21.7%
Reported: 0% | M&A: 0% | FX: -1%		+30 bps y/y

- +LDD ImmunoDX globally, China ImmunoDX +high-teens
- +LSD Reproductive Health with +MSD newborn (+LDD ex. China)
- -Mid-20%'s Applied Genomics decline as expected driven by Pharma/Biotech headwinds

2024 Financial Guidance

REVENUE	**$2.76B - $2.82B**
	0% to 3% reported
	Organic: 1% to 3%
	FX: 0%, M&A: 0%
ADJUSTED OP. MARGIN	**~28%**
ADJUSTED EPS	**$4.55 - $4.75**
	Adj. Net interest expense, other: ~$60M
	Adjusted tax rate: ~20%
	Average diluted share count: 123.5M

Revvity.com